SinoMab Sells Suzhou Facility at a Loss; Everest Medicines Completes Civorebrutinib (EVER001) BD Deal Closing
Everest Medicines
Developer of Innovative Therapies
Travere Therapeutics
Pharmaceutical R&D Developer
Vertex
Breakthrough Small Molecule Drug Developer
Qihan Biotech
Gene Editing Technology Developer
InventisBio
Innovative Drug Developer
Amino Observation - Original Production by the Innovative Drug Group
Author | Huang Kai
SINOMAB BIOSCIENCE LIMITED Stops Loss.
On July 6, SINOMAB BIOSCIENCE LIMITED announced that its wholly-owned subsidiary intends to sell the entire biopharmaceutical land, plant, production equipment, and supporting facilities located in Suzhou Industrial Park for RMB 280 million. This transaction directly resulted in the company recognizing a non-operating loss of approximately RMB 56 million on its books.
Everest Speed.
On July 7, Everest Medicines announced that it had completed the closing of the exclusive license and collaboration agreement with Travere Therapeutics regarding EVER001 (civorebrutinib) in accordance with the terms of the agreement.
Vertex Acquires New Drug for Acromegaly for $10 Billion.
On July 6, Vertex announced that it would acquire Crinetics for $85.00 per share in cash, with a total equity value of approximately $10 billion. Crinetics’ most advanced investigational candidate, atumelnant, is a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist currently in Phase III development for congenital adrenal hyperplasia (CAH).
What Other Hot Topics in the Domestic and International Pharmaceutical Markets Are Worth Paying Attention to Over the Past Day? Let Amin Jun Take You on a Deep Dive.
/ 01 /
Market Flash
1) Sinomab Bioscience Sells Suzhou Factory at a Loss
On July 6, SINOMAB BIOSCIENCE LIMITED announced that its wholly-owned subsidiary intends to sell the entire biopharmaceutical land, plant, production equipment, and supporting facilities located in Suzhou Industrial Park for RMB 280 million. This transaction directly resulted in the company recognizing a non-operating loss of approximately RMB 56 million on its books.
2) Everest Medicines Completes BD Closing for Xibitinib
On July 7, Everest Medicines announced that it had completed the closing of the exclusive license and collaboration agreement with Travere Therapeutics regarding EVER001 (civorebrutinib) in accordance with the terms of the agreement.
/ 02 /
Pharmaceutical Updates
1) Qihan Biotech's QT-019C Cell Injection Receives Clinical Trial Approval
On July 7, according to the official website of the Center for Drug Evaluation (CDE), Qihan Biotech’s QT-019C cell injection received clinical trial approval, with plans to conduct research on the treatment of moderate-to-severe refractory systemic lupus erythematosus.
2) InventisBio’s YF087 Tablets Receive Clinical Trial Approval
On July 7, according to the official website of the Center for Drug Evaluation (CDE), InventisBio’s YF087 tablets received clinical trial approval for the proposed treatment of advanced solid tumors with high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR).
3) Cytopeutics’ SPGL008 Injection Receives Clinical Trial Approval
On July 7, according to the official website of the Center for Drug Evaluation (CDE), Saibaoer Biologics’ SPGL008 injection received clinical trial approval for use in combination with SSGJ-706 ± chemotherapy for the treatment of advanced non-small cell lung cancer.
4) Roche’s RO7435846 Tablets Receive Clinical Trial Approval
On July 7, according to the CDE website, Roche’s RO7435846 tablets received clinical trial approval for a study intended to treat early-stage non-small cell lung cancer (NSCLC) with KRAS G12C mutations.
/ 03 /
Overseas Pharma News
1) $10 Billion: Vertex Acquires New Drug for Acromegaly
On July 6, Vertex announced that it would acquire Crinetics for $85.00 per share in cash, with a total equity value of approximately $10 billion. Crinetics’ most advanced investigational candidate, atumelnant, is a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist currently in Phase III development for congenital adrenal hyperplasia (CAH).